Novartis: Idelalisib approved for first-line treatment of CLL/SLL in China.

The announcement of NovaSheng Jianhua: the company's core product, Ibrutinib, has been approved by the China National Medical Products Administration for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma patients. Previously, Ibrutinib had been approved in China for the treatment of CLL/SLL, mantle cell lymphoma, and marginal zone lymphoma patients who had received at least one prior therapy, and had been included in the national medical insurance drug list. The approval for first-line CLL/SLL treatment this time will benefit more lymphoma patients.